A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Na ve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer

Brief description of study

A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer


Clinical Study Identifier: s23-00493
ClinicalTrials.gov Identifier: NCT05669664
Principal Investigator: Zujun Li.
Other Investigators: Tuyet-Phuong N Tran, Elaine Shum, Adam S Jacobson, Michael Persky, Joshua K Sabari, Catherine M Concert, Elise M Zahriah, Colin Hill, Ann M Riccobene, Caitlin Elizabeth Ryan, Megan DiBenedetto, Ruth A White, Kenneth S Hu.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.